ENDONOVO THERAPEUTICS, INC. Stock-Based Compensation
ENDONOVO THERAPEUTICS, INC. (ENDV) reported Stock-Based Compensation of $6.00 thousand for the 9-month period ending 2023-09-30, per its 10-Q filed 2023-12-29.
Discontinued › Cash Flow › Operating Activities
us-gaap:ShareBasedCompensation · last filed 2023-12-29
- ENDONOVO THERAPEUTICS, INC. share-based payment arrangement, noncash expense for the quarter ending 2023-09-30 was $0.00.
- ENDONOVO THERAPEUTICS, INC. share-based payment arrangement, noncash expense for the quarter ending 2023-06-30 was $3.44K.
- ENDONOVO THERAPEUTICS, INC. share-based payment arrangement, noncash expense for the quarter ending 2023-03-31 was $2.56K.
- ENDONOVO THERAPEUTICS, INC. share-based payment arrangement, noncash expense for the quarter ending 2022-09-30 was $0.00, a 100.00% decline year-over-year.
- ENDONOVO THERAPEUTICS, INC. share-based payment arrangement, noncash expense for fiscal 2021 was $0.00, a 100.00% decline from fiscal 2020.
- ENDONOVO THERAPEUTICS, INC. share-based payment arrangement, noncash expense for fiscal 2020 was $57.40K, a 85.09% increase from fiscal 2019.
- ENDONOVO THERAPEUTICS, INC. share-based payment arrangement, noncash expense for fiscal 2019 was $31.01K.
| Period end | Share-based Payment Arrangement, Noncash Expense 3 month | Share-based Payment Arrangement, Noncash Expense 6 month | Share-based Payment Arrangement, Noncash Expense 9 month | Share-based Payment Arrangement, Noncash Expense 12 month |
|---|---|---|---|---|
| 2023-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2023-12-29 | $3.44K derived: sum of 2 quarters · filed 2023-12-29 | $6.00K 10-Q · filed 2023-12-29 | |
| 2023-06-30 | $3.44K derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-21 | $6.00K 10-Q · filed 2023-08-21 | ||
| 2023-03-31 | $2.56K 10-Q · filed 2023-05-22 | |||
| 2022-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2023-12-29 | $0.00 10-Q · filed 2023-12-29 | ||
| 2022-06-30 | $0.00 10-Q · filed 2023-08-21 | |||
| 2021-12-31 | -$61.00K derived: 10-K 12 month − 10-Q 9 month · filed 2022-04-14 | -$40.96K derived: sum of 2 quarters · filed 2022-11-21 | -$20.47K derived: sum of 3 quarters · filed 2022-11-21 | $0.00 10-K · filed 2022-04-14 |
| 2021-09-30 | $20.04K derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-21 | $40.53K derived: sum of 2 quarters · filed 2022-11-21 | $61.00K 10-Q · filed 2022-11-21 | -$281.71K derived: sum of 4 quarters · filed 2022-11-21 |
| 2021-06-30 | $20.49K derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-22 | $40.96K 10-Q · filed 2022-08-22 | -$301.75K derived: sum of 3 quarters · filed 2022-08-22 | $42.82K derived: sum of 4 quarters · filed 2022-08-22 |
| 2021-03-31 | $20.47K 10-Q · filed 2022-05-19 | -$322.24K derived: sum of 2 quarters · filed 2022-05-19 | $22.33K derived: sum of 3 quarters · filed 2022-05-19 | $68.30K derived: sum of 4 quarters · filed 2022-05-19 |
| 2020-12-31 | -$342.71K derived: 10-K 12 month − 10-Q 9 month · filed 2022-04-14 | $1.86K derived: sum of 2 quarters · filed 2022-04-14 | $47.83K derived: sum of 3 quarters · filed 2022-04-14 | $57.40K 10-K · filed 2022-04-14 |
| 2020-09-30 | $344.57K derived: 10-Q 9 month − 10-Q 6 month · filed 2020-11-19 | $390.54K derived: sum of 2 quarters · filed 2020-11-19 | $400.11K 10-Q · filed 2020-11-19 | |
| 2020-06-30 | $45.97K derived: 10-Q 6 month − 10-Q 3 month · filed 2020-08-19 | $55.54K 10-Q · filed 2020-08-19 | ||
| 2020-03-31 | $9.57K 10-Q · filed 2021-05-24 | |||
| 2019-12-31 | $31.01K 10-K · filed 2021-04-13 | |||
| 2017-06-30 | $1.00M 10-Q · filed 2018-08-13 |